The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

Published:2016-01-13 Issue:1 Volume:35 Page:91-98
ISSN:0914-8779
Container-title:Journal of Bone and Mineral Metabolism
language:en
Short-container-title:J Bone Miner Metab

Author:

Ebina Kosuke,Hashimoto Jun,Kashii Masafumi,Hirao Makoto,Kaneshiro Shoichi,Noguchi Takaaki,Tsukamoto Yasunori,Yoshikawa Hideki

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,General Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/article/10.1007/s00774-015-0731-x/fulltext.html

Reference26 articles.

1. Yamamoto T, Taketsuna M, Guo X, Sato M, Sowa H (2014) The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report. J Bone Miner Metab 32:699–708

2. Lee SK, Lorenzo JA (2002) Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. Bone 31:252–259

3. Gallacher SJ, Dixon T (2010) Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int 87:469–484

4. Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H (2013) Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res 28:196–205

5. Obermayer-Pietsch BM, Marin F, McCloskey EV et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23:1591–1600

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert opinion on the management of patients with osteoporosis with anabolic drugs in Italy;Reumatismo;2024-06-24

2. Vertebroplasty, Kyphoplasty, and Sacroplasty;Essentials of Interventional Techniques in Managing Chronic Pain;2024

3. Five‐Year Outcomes of Continuous Treatment with Zoledronic Acid Versus Denosumab in Older Men with High Fracture Risk: Risk Factor Analysis of Bone Density Improvement and Incidence of New Fracture;The Journal of Clinical Pharmacology;2023-11-16

4. Quel relais thérapeutique à une séquence de tériparatide dans l’ostéoporose ? Comparaison de différents agents anti-ostéoclastiques sur l’évolution densitométrique;Revue du Rhumatisme;2023-10

5. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study;Endocrine;2023-07-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3